News & Updates
Filter by Specialty:
Weekly dose-dense CT does not confer survival benefit for ovarian cancer patients
In the final analysis of the phase III ICON8* study, a weekly dose-dense chemotherapy (CT) regimen comprising paclitaxel and carboplatin did not improve survival outcomes in women with epithelial ovarian cancer** compared with the standard first-line (1L) paclitaxel-carboplatin regimen given once every 3 weeks (Q3W).
Weekly dose-dense CT does not confer survival benefit for ovarian cancer patients
18 Jul 2022
Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.
Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
18 Jul 2022
Is laparoscopic better than open partial nephrectomy for renal tumours?
Patients with renal tumours who have undergone laparoscopic partial nephrectomy (LPN) have shown similar surgical and oncologic outcomes as those treated with open partial nephrectomy (OPN), reports a study.